Note 12 - Segment Information

3 Months Ended

Mar. 31, 2025

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

12. Segment Information

Segment reporting is prepared on the same basis that our chief executive officer, who is our CODM, manages the business, makes operating decisions and assesses performance. The Company operates in one segment. The Company’s business is research and development of drug candidates. Costs, including supplies, outsourced development, and other research and development costs are tracked by major program. While internal personnel costs are tracked by program for overall program spending, it is not broken out for management review. Facility and equipment costs are not allocated to programs. Research and development expenses are summarized by program in the table below:

	Three-Months Ended March 31,
	2025			2024
	(000's)
Personnel	$	3,202		$	2,761
General		1,210			999
Tovecimig		6,677			4,497
CTX-471		699			679
CTX-8371		529			586
CTX-10726		737			—
Research and development		13,054			9,522
Personnel		1,594			944
General		1,611			1,225
Stock-based compensation		1,707			1,079
General and administrative		4,912			3,248
Other income		1,333			1,983
Net loss	$	(16,633	)	$	(10,787	)